Lisata Therapeutics (NASDAQ:LSTA) Posts Quarterly Earnings Results, Beats Expectations By $0.05 EPS

Lisata Therapeutics (NASDAQ:LSTA) announced its quarterly earnings results on Thursday. The company reported ($0.49) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.05, Zacks reports.

Lisata Therapeutics Trading Down 12.3%

Shares of Lisata Therapeutics stock traded down $0.29 during trading hours on Friday, hitting $2.06. 95,200 shares of the company were exchanged, compared to its average volume of 42,577. The business has a 50-day moving average of $2.40 and a 200-day moving average of $2.51. Lisata Therapeutics has a 1 year low of $1.87 and a 1 year high of $4.20. The stock has a market capitalization of $18.04 million, a price-to-earnings ratio of -0.92 and a beta of 1.01.

Analyst Upgrades and Downgrades

A number of research firms recently commented on LSTA. Brookline Capital Management increased their target price on shares of Lisata Therapeutics from $20.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, July 15th. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective on shares of Lisata Therapeutics in a report on Thursday, August 21st. Zacks Research upgraded Lisata Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Friday, October 10th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Lisata Therapeutics in a research report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $23.50.

Institutional Trading of Lisata Therapeutics

An institutional investor recently bought a new position in Lisata Therapeutics stock. Cerity Partners LLC bought a new stake in Lisata Therapeutics, Inc. (NASDAQ:LSTA) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 12,183 shares of the company’s stock, valued at approximately $32,000. Cerity Partners LLC owned approximately 0.14% of Lisata Therapeutics as of its most recent SEC filing. Institutional investors own 8.94% of the company’s stock.

Lisata Therapeutics Company Profile

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.